TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10404055

Group type: EXPERIMENTAL
Intervention: IVIG treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-IVIG treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study: 7590046

Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine 20 mg plus inhaled oxygen on demand
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide on demand
Number of subjects: 131

Group type: COMPARATOR
Intervention: Sterile water injection plus inhaled oxygen on demand (placebo)
Number of subjects: 131
Study: 2082315

Group type: COMPARATOR
Intervention: Oral ketorolac 10 mg
Number of subjects: 747

Group type: COMPARATOR
Intervention: Oral ketorolac 12.5 mg
Number of subjects: 747

Group type: COMPARATOR
Intervention: Oral ketorolac 100 mg
Number of subjects: 747

Group type: COMPARATOR
Intervention: Oral ketorolac 200 mg
Number of subjects: 747

Group type: COMPARATOR
Intervention: Intramuscular ketorolac 90 mg
Number of subjects: 747

Group type: COMPARATOR
Intervention: Intramuscular ketorolac 10 mg
Number of subjects: 747

Group type: COMPARATOR
Intervention: Intramuscular ketorolac 30 mg
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac 10 mg and 30 mg
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Ketorolac doses of 2.5 and 5 mg
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Ketorolac doses of 10 mg or more
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Ketorolac doses of 90 mg or more
Number of subjects: 747
Study: 476711

Group type: EXPERIMENTAL
Intervention: Five-drug regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Two-drug regimen (cyclophosphamide and vincristine)
Number of subjects: 26
Study: 6851562

Group type: EXPERIMENTAL
Intervention: 21-day low-dose combined pill
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 21-day low-dose combined pill followed by 7 days of iron-containing pill
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 63-day low-dose combined pill followed by 7 days of no pill intake
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lippes IUD
Number of subjects: 150

Group type: COMPARATOR
Intervention: TCu 220C
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Progestasert
Number of subjects: 150
Study: 30632796

Group type: EXPERIMENTAL
Intervention: High self-efficacy (HSE)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low self-efficacy (LSE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Neutral self-efficacy (NSE)
Number of subjects: 62
Study: 28318923

Group type: EXPERIMENTAL
Intervention: Two-dimensional prediction technique
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three-dimensional prediction technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 27004282

Group type: EXPERIMENTAL
Intervention: Fit restorations (assembled by an intraoral bonding procedure)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Misfit restorations (cast in one piece)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fit restorations
Number of subjects: 20

Group type: COMPARATOR
Intervention: Misfit restorations
Number of subjects: 20
Study: 24286591

Group type: EXPERIMENTAL
Intervention: Hypoxic training (HT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normoxic training (NT)
Number of subjects: 40
Study: 22252613

Group type: EXPERIMENTAL
Intervention: Z- BEAM (Ibritumomab tiuxetan at 0.4 mCi/kg on day -14 before ASCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: BEAM alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Z- BEAM
Number of subjects: 43
Study: 19968839

Group type: EXPERIMENTAL
Intervention: Benznidazole (two doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-parasitaemic newborns (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CSP test (immunochromatography)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chagatest v3.0 (ELISA)
Number of subjects: 0
Study: 18198318

Group type: EXPERIMENTAL
Intervention: Maintenance program delivered face-to-face
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Maintenance program delivered via the Internet
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 314
Study: 15857208

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Melon juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Grape juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Peach juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Plum juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apple juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Kiwi juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Watermelon juice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pear juice
Number of subjects: 10
Study: 12077585

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (methylprednisolone aceponate)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Systemic antifungal (terbinafine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Systemic antifungal (itraconazole)
Number of subjects: 45
Study: 9579491

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 7
Study: 7650352

Group type: EXPERIMENTAL
Intervention: Relaxation with guided imagery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 2668427

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g every 24 h)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Cefotaxime (2 g every 6 h)
Number of subjects: 325
Study: 327944

Group type: EXPERIMENTAL
Intervention: Intramuscular salbutamol 20 microgram/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36
Study: 31769299

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (group cognitive rehabilitation programme delivered in 10 weekly sessions)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 449
Study: 30561849

Group type: EXPERIMENTAL
Intervention: Prednisolone and oral vitamin D (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prednisolone (n=15, control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (n=30)
Number of subjects: 30
Study: 28547999

Group type: COMPARATOR
Intervention: Handwriting intervention (self-managed at home, 1 hour, twice weekly for 6 months)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (exercise intervention in community facilities)
Number of subjects: 105
Study: 26017268

Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (general non-psychotic psychiatric outpatient sample), n = 110
Number of subjects: 133
Study: 23394408

Group type: EXPERIMENTAL
Intervention: Information film about prenatal examinations
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (no information film)
Number of subjects: 390
Study: 21312328

Group type: EXPERIMENTAL
Intervention: Newly laundered short‐sleeved uniforms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Physicians' white coats
Number of subjects: 100
Study: 19058890

Group type: EXPERIMENTAL
Intervention: Half a year of clinical work before an ALS course
Number of subjects: 117

Group type: COMPARATOR
Intervention: Immediate participation in an ALS course following graduation (Control)
Number of subjects: 117
Study: 17376996

Group type: EXPERIMENTAL
Intervention: Navigator correction
Number of subjects: 83
Study: 15586803

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.5% applied topically for 5 minutes after ESS
Number of subjects: 29

Group type: COMPARATOR
Intervention: Saline (control) applied topically for 5 minutes after ESS
Number of subjects: 29
Study: 11183450

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Olopatadine hydrochloride 0.1%
Number of subjects: 28
Study: 8979142

Group type: EXPERIMENTAL
Intervention: Prolonged prophylaxis against postoperative venous thromboembolism
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard prophylaxis (7-14 days)
Number of subjects: 0
Study: 1424850

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training combined with general exercise reconditioning
Number of subjects: 36

Group type: COMPARATOR
Intervention: General exercise reconditioning alone
Number of subjects: 36

Group type: COMPARATOR
Intervention: No training
Number of subjects: 36
Study: 4050528

Group type: EXPERIMENTAL
Intervention: Amipaque (metrizamide)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Isopaque Coronar (meglumine-Na-Ca-metrizoate)
Number of subjects: 99
Study: 30651989

Group type: EXPERIMENTAL
Intervention: High fidelity simulation (HF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low fidelity simulation (LF)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham simulation (S)
Number of subjects: 90
Study: 30021633

Group type: EXPERIMENTAL
Intervention: Softec HD™ IOL (0.25 D interval)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Akreos AO IOL (0.50 D interval)
Number of subjects: 40
Study: 28399988

Group type: EXPERIMENTAL
Intervention: Y-SBNT (adapted youth social behaviour and network therapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 53
Study: 26143666

Group type: EXPERIMENTAL
Intervention: Presence of SHRM at enrollment (77%), at 4 weeks (68%), and at 104 weeks (54%).
Number of subjects: 1185

Group type: COMPARATOR
Intervention: Eyes with persistent SHRM at 104 weeks showed scar presence (64%) compared to those with resolved SHRM (31%).
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Mean VA letter scores for SHRM status: absent (73.5), present outside central 1 mm² (73.1), present within central 1 mm² but not foveal center (65.3), present at foveal center (63.9).
Number of subjects: 1185

Group type: EXPERIMENTAL
Intervention: Median maximum SHRM height under the fovea: 86 μm (absent), 120 μm (outside central 1 mm²), 122 μm (within central 1 mm²).
Number of subjects: 1185
Study: 24868255

Group type: EXPERIMENTAL
Intervention: Combination of fat graft, laser CO2, and platelet-rich plasma (PRP)
Number of subjects: 64
Study: 20305407

Group type: EXPERIMENTAL
Intervention: Tc-99m sestamibi
Number of subjects: 23

Group type: COMPARATOR
Intervention: Tc-99m pertechnetate
Number of subjects: 23
Study: 18979616

Group type: EXPERIMENTAL
Intervention: Yoghurt containing 1 g plant sterols (Study I)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Yoghurt containing 2 g plant sterols (Study II)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sterol yoghurt (combined results from both studies)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo yoghurt (Study I and Study II)
Number of subjects: 27
Study: 16610925

Group type: EXPERIMENTAL
Intervention: Recycling intervention strategy to increase tobacco dependence treatment rates
Number of subjects: 951
Study: 14506832

Group type: EXPERIMENTAL
Intervention: Modified lard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lard
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both meals (modified lard and lard)
Number of subjects: 0
Study: 10907668

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25, 0.50, 0.75 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Buspirone (5, 10, 15 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8994313

Group type: EXPERIMENTAL
Intervention: HbOC
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: PRP-T
Number of subjects: 319

Group type: COMPARATOR
Intervention: Interchangeable products (HbOC or PRP-T)
Number of subjects: 319

Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 319
Study: 1451900

Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 50 mg pethidine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 100 mg pethidine
Number of subjects: 3
Study: 6499355

Group type: EXPERIMENTAL
Intervention: Verapamil (240 to 480 mg%)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol (120 to 360 mg%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil (480 mg%)
Number of subjects: 24
Study: 29444275

Group type: EXPERIMENTAL
Intervention: Health condition (harm reduction themed ads)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Social condition (social enhancement themed ads)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control condition (ads of everyday objects only)
Number of subjects: 393
Study: 29102613

Group type: EXPERIMENTAL
Intervention: Gluten (5.7 g)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Fructans (2.1 g)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 28268330

Group type: EXPERIMENTAL
Intervention: High adherence to self-monitoring of diet and moderate adherence to glucose self-monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clusters with high or low adherence to self-monitoring of all four factors
Number of subjects: 0
Study: 25543688

Group type: EXPERIMENTAL
Intervention: Five face-to-face counseling sessions
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: One face-to-face counseling session followed by four telephone calls
Number of subjects: 261

Group type: COMPARATOR
Intervention: Generic mailed physical activity brochure (usual care)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Combined intervention group (face-to-face and telephone)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 261
Study: 22901398

Group type: EXPERIMENTAL
Intervention: Newsletter prenotification
Number of subjects: 1342

Group type: COMPARATOR
Intervention: No newsletter prenotification
Number of subjects: 1342
Study: 20384600

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 18227539

Group type: EXPERIMENTAL
Intervention: Radiography and MR imaging (n = 96)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Radiography alone (n = 93)
Number of subjects: 189
Study: 16317121

Group type: EXPERIMENTAL
Intervention: Isoflavones
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides
Number of subjects: 39
Study: 14612852

Group type: EXPERIMENTAL
Intervention: Cyclo 3 Fort
Number of subjects: 10246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10246
Study: 10390389

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms twice daily (FP200)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms twice daily (FP100)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 8219927

Group type: EXPERIMENTAL
Intervention: Preoperative administration of acetaminophen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no acetaminophen)
Number of subjects: 0
Study: 3691593

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg daily
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 29366431

Group type: EXPERIMENTAL
Intervention: 5mg prednisolone in the evening
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5mg prednisolone in the morning
Number of subjects: 8
Study: 27325340

Group type: EXPERIMENTAL
Intervention: Ranking without sorting
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Ranking and sorting
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control (present EQ-5D-5L study protocol, without ranking)
Number of subjects: 600
Study: 26075375

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (HD)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Transparent polyurethane film (PF)
Number of subjects: 160
Study: 23489892

Group type: EXPERIMENTAL
Intervention: Annual mammography for at least 5 years
Number of subjects: 6710

Group type: COMPARATOR
Intervention: Control group from the UK Breast Screening Age Trial
Number of subjects: 6710
Study: 21681888

Group type: EXPERIMENTAL
Intervention: Export catheter (Medtronic, Minneapolis, MN)
Number of subjects: 201

Group type: COMPARATOR
Intervention: X-sizer system (eV3, White Bear Lake, MN)
Number of subjects: 201
Study: 19366752

Group type: EXPERIMENTAL
Intervention: Intervention group (home visits by lay community workers providing support and guidance in parenting)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group (no therapeutic input)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 449
Study: 16625238

Group type: EXPERIMENTAL
Intervention: Cilnidipine for 2 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no cilnidipine)
Number of subjects: 40
Study: 15162946

Group type: EXPERIMENTAL
Intervention: Inhaled steroids (Beclomethasone) plus prolonged action bronchodilator (Salmeterol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled steroids (Beclomethasone)
Number of subjects: 30
Study: 11458057

Group type: EXPERIMENTAL
Intervention: Polyestradiol phosphate (240 mg intramuscular injections every 2 weeks for 8 weeks, then monthly)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Complete androgen ablation (bilateral orchiectomy or 3.75 mg triptorelin monthly with 250 mg flutamide 3 times daily)
Number of subjects: 915
Study: 10089183

Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted to achieve an INR of 2.0 to 3.0)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 162
Study: 7917165

Group type: COMPARATOR
Intervention: Unweighted condition (no additional weight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Addition of 0.68 kg to the shank
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Addition of 1.34 kg to the shank
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Self-selected walking speed
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control speeds (0.6, 1.0, and 1.5 m/s)
Number of subjects: 8
Study: 2697567

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study: 1100014

Group type: EXPERIMENTAL
Intervention: 5,000 international units aqueous heparin sodium
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 30456795

Group type: EXPERIMENTAL
Intervention: Standard BurstDR stimulation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Microdosing A (5 sec of BurstDR alternating with 5 sec of no stimulation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Microdosing B (5 sec of BurstDR alternating with 10 sec of no stimulation)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Microdosing A and B
Number of subjects: 25
Study: 28874235

Group type: EXPERIMENTAL
Intervention: rhC1‐INH (50 IU/kg for patients <84 kg; 4200 IU for patients ≥84 kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: rhC1‐INH (during OLE study)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (during OLE study)
Number of subjects: 75
Study: 26083955

Group type: EXPERIMENTAL
Intervention: Comprehensive Psychosocial Intervention (CPI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual Community Care (UCC)
Number of subjects: 180
Study: 23465176

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 333

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 333
Study: 21628010

Group type: EXPERIMENTAL
Intervention: Various endoscopic technologies (e.g., colonoscopy, third eye retroscope, cap-fitted, cap-assisted)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 18993031

Group type: COMPARATOR
Intervention: Switching to other medications from olanzapine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Staying on olanzapine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Switching to other medications from risperidone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Staying on risperidone
Number of subjects: 129

Group type: COMPARATOR
Intervention: Switching from quetiapine
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Staying on quetiapine
Number of subjects: 129
Study: 16550824

Group type: EXPERIMENTAL
Intervention: Prostamol Uno 320 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 54
Study: 12856138

Group type: EXPERIMENTAL
Intervention: Controlled ileal-release budesonide (9 mg by mouth)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 10865008

Group type: EXPERIMENTAL
Intervention: Electrocardiogram (EKG)
Number of subjects: 749

Group type: EXPERIMENTAL
Intervention: Chest Radiogram (x-ray)
Number of subjects: 749

Group type: COMPARATOR
Intervention: Clinical examination without EKG and x-ray
Number of subjects: 749
Study: 9333132

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (2 h/day, 5 days/week for 5 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 38
Study: 7687421

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with hyperthermia (HCR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Chemotherapy alone (Group A)
Number of subjects: 21
Study: 3772566

Group type: EXPERIMENTAL
Intervention: Sharing medical records with smokers (experimental group)
Number of subjects: 401

Group type: COMPARATOR
Intervention: No sharing of medical records (control group)
Number of subjects: 401